These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37240695)

  • 1. Association between Cerebrospinal Fluid Soluble
    Zhou W; Zhou Y; Li J
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.
    Wang R; Zhan Y; Zhu W; Yang Q; Pei J
    Front Aging Neurosci; 2024; 16():1407980. PubMed ID: 38841103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age Matching Is Essential for the Study of Cerebrospinal Fluid sTREM2 Levels and Alzheimer's Disease Risk: A Meta-Analysis.
    Hu S; Pan N; Liu C; Wang Y; Zhang T
    Front Aging Neurosci; 2021; 13():775432. PubMed ID: 34867303
    [No Abstract]   [Full Text] [Related]  

  • 5. Soluble TREM2 in body fluid in Alzheimer's disease and Parkinson's disease.
    Gu L; Shu H; Wang Y
    Neurol Sci; 2023 Aug; 44(8):2743-2751. PubMed ID: 36913148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease.
    Španić Popovački E; Babić Leko M; Langer Horvat L; Brgić K; Vogrinc Ž; Boban M; Klepac N; Borovečki F; Šimić G
    Neurol Int; 2023 Jul; 15(3):842-856. PubMed ID: 37489359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes.
    Pillai JA; Khrestian M; Bena J; Leverenz JB; Bekris LM
    Front Aging Neurosci; 2021; 13():676744. PubMed ID: 34276339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease.
    Zhao A; Jiao Y; Ye G; Kang W; Tan L; Li Y; Deng Y; Liu J;
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
    Li TR; Lyu DY; Liu FQ;
    J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer's Disease.
    Liu C; Yu J
    Front Aging Neurosci; 2019; 11():297. PubMed ID: 31708768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease.
    Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE
    J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
    Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
    Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between cerebrospinal ferritin and soluble triggering receptor expressed on myeloid cells 2 along Alzheimer's continuum.
    Shi X; Zhong X; Zhou H; Zhou N; Hu Y; Ning Y;
    Front Neurol; 2022; 13():961842. PubMed ID: 36408515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?
    Ferri E; Rossi PD; Geraci A; Ciccone S; Cesari M; Arosio B
    Front Mol Biosci; 2020; 7():627931. PubMed ID: 33768114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.
    Wu C; Ma YH; Hu H; Zhao B; Tan L;
    J Alzheimers Dis; 2023; 92(1):311-322. PubMed ID: 36744335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels.
    Hou XH; Bi YL; Tan MS; Xu W; Li JQ; Shen XN; Dou KX; Tan CC; Tan L; ; Yu JT
    Neurobiol Aging; 2019 Dec; 84():241.e13-241.e20. PubMed ID: 31204042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification.
    Knapskog AB; Henjum K; Idland AV; Eldholm RS; Persson K; Saltvedt I; Watne LO; Engedal K; Nilsson LNG
    Sci Rep; 2020 Sep; 10(1):15886. PubMed ID: 32985583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.